Computational Evolution of Anti-PD-1 Antibodies Induces Structural Refolding for High-Affinity Interactions
- 11 February 2026
- journal article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 65 (5) , 517-520
Abstract
Checkpoint inhibitors targeting the PD-1/PD-L1 axis are key immunotherapies, but the dynamic and flexible nature of PD-1 complicates rational antibody engineering. Here, we use computational saturation mutagenesis, AlphaFold prediction, and molecular dynamics (MD) simulations to evolve pembrolizumab variants with suitable binding. Seven engineered antibodies form additional salt bridges and hydrophobic contacts via refolding of both the antibody and the PD-1 interface. One variant, m7p.5, displays improved biphasic kinetics and high-affinity binding (KD,apparent = 62 pM). Structural changes include an α-helix to loop transition in the antibody heavy chain and a 4.6-Å Cα shift of a PD-1 loop. These results show that computational evolution can access binding modes inaccessible to traditional rigid structural design, enabling high-affinity antibodies for flexible targets. It is demonstrated that our integrated computational approaches including MD simulations can generate new picomolar high-affinity antibodies targeting specific epitopes of proteins that may be intrinsically flexible and are difficult to target with reasonable computational cost, which would be far less than an experimental cost for finding new antibodies with equivalent binding affinities. This study provides a new tool that can be combined with other artificial-intelligence-based antibody generation against PD-1 from the existing anti-PD-1 antibody library with broad applications in protein-protein interactions.Keywords
Funding Information
- National Institute of General Medical Sciences (R01 GM136815)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R00HD104924)
This publication has 17 references indexed in Scilit:
- Binding Curve Viewer: Visualizing the Equilibrium and Kinetics of Protein–Ligand Binding and Competitive BindingJournal of Chemical Information and Modeling, 2024
- AmberToolsJournal of Chemical Information and Modeling, 2023
- Structural Insights into Binding of Remdesivir Triphosphate within the Replication–Transcription Complex of SARS-CoV-2Biochemistry, 2022
- Insights into Binding of Single-Stranded Viral RNA Template to the Replication–Transcription Complex of SARS-CoV-2 for the Priming Reaction from Molecular Dynamics SimulationsBiochemistry, 2022
- Arginine “Magic”: Guanidinium Like-Charge Ion Pairing from Aqueous Salts to Cell Penetrating PeptidesAccounts of Chemical Research, 2018
- Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2Structure, 2017
- Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatmentInternational Immunopharmacology, 2017
- Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapyNature Communications, 2016
- Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumabCell Research, 2016
- Contribution of unusual Arginine-Arginine short-range interactions to stabilization and recognition in proteinsThe Protein Journal, 1994